|
Explicative variables
|
Relative risk (95% CI)
|
p-value
|
|---|
|
Tumor size
|
2.04 (1.412–2.95)
|
0.00015
|
|
Grade 1
|
-
|
-
|
|
Grade 2
|
1.38 (0.30–6.30)
|
0.679
|
|
Grade 3
|
2.92 (0.63–13.54)
|
0.171
|
|
Relapse
|
14.95 (5.67–39.44)
|
<0.0001
|
|
EBV-T
+
|
0.795 (0.291–2.173)
|
0.65
|
|
EBV-P
+
|
1.05 (0.44–2.51)
|
0.91
|
|
ER/PR positive
|
0.48 (0.19–1.20)
|
0.116
|
|
HER-2 positive
|
2.71 (0.795–9.21)
|
0.111
|
|
Lymph node invasion
|
6.32 (2.31–17.3)
|
0.0003
|
|
Anti-ZEBRA antibody titration
|
4,63 (1.75–12.23)
|
0.002
|
- EBV: Epstein-Barr virus; T+: detected in tumors; P+: detected in PBMCs; ER/PR: estrogen/progesterone receptor; HER-2: human epidermal growth factor receptor 2; anti-ZEBRA: antibodies to BamH1 Z Epstein-Barr replication activator.
